PALISADE CAPITAL MANAGEMENT, LP - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is and the CUSIP is 40637HAD1. A total of 64 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
PALISADE CAPITAL MANAGEMENT, LP ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,342,631
-25.4%
2,768,000
-26.5%
0.06%
-22.6%
Q2 2023$3,139,874
-6.4%
3,768,000
-4.9%
0.08%
-7.7%
Q1 2023$3,354,229
+2.8%
3,962,000
+18.2%
0.09%
+3.4%
Q4 2022$3,264,010
-9.7%
3,352,000
-21.1%
0.09%
-13.7%
Q3 2022$3,613,000
+309.2%
4,250,000
+325.0%
0.10%
+325.0%
Q2 2022$883,0001,000,0000.02%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Wellesley Asset Management 71,432$63,617,0004.32%
Western Asset Management Company, LLC 15,600,000$13,690,0004.04%
CAMDEN ASSET MANAGEMENT L P /CA 70,849,000$61,727,0001.84%
ZAZOVE ASSOCIATES LLC 16,992,000$14,985,0001.32%
Penn Mutual Asset Management, LLC 1,305,000$1,137,0001.32%
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP 64,750,000$56,413,0000.72%
CQS (US), LLC 10,000,000$8,777,0000.61%
ADVENT CAPITAL MANAGEMENT /DE/ 28,859,000$25,319,0000.40%
Context Capital Management, LLC 4,122$3,632,0000.24%
Hudson Bay Capital Management LP 19,500,000$17,152,0000.23%
View complete list of HALOZYME THERAPEUTICS INC shareholders